of a total results good summary with high-level everyone. and year performance the QX Then guidance. comments on conclude our for XXXX initial full Thanks, and begin I'll some with color company. provide segments morning, I'll our our and Marc, X around
in Similar growth organic As of year press XX% elements. achieved organic QX. and you full into grew XX%. quarters, our break release, the exceptional quarter growth saw This I'll in an previous down X organically resulted in to we
revenue. and the scale improvement. QX, is organically, business performance COVID-XX of the of of another quarter In grew response the base base first The the is the sequential the business second X%
base For the commercial flat by in a offset year, activity result full pandemic, great was economic the year partially business essentially earlier as due to the slower execution. the of
in $X.X earnings for revenue XXXX adjusted fourth we and is growth significantly in noting also revenue to for we instruments. of Business also million bringing the XX% support PPI that therapies. COVID-XX for largely $XXX impact Our products response increased testing-related quarter XXX% enabled COVID-XX-related vaccines $X.X full billion, System again, and the by share per in billion. full from delivered generated in QX It year This worth year. Once customers to was our our pull-through, excellent the and and driven
flow. XX% in us $X.X strong cash cash year. PPI the was System flow versus year results Our Overall for prior XXXX. also to generate extremely Business enabled up financial exceptional Free billion, the
me Let with performance, you on more earnings starting our results. details with QX provide now some our
-- As we XXX% I by EPS EPS adjusted grew $X.XX. mentioned, to
year. was For XX% was adjusted in was to EPS the XXX% $X.XX, up the GAAP full up year, $XX.XX, last EPS EPS up full year. XXXX year GAAP And prior year. XX% from versus quarter QX $XX.XX, compared last
from On XX% QX reported foreign and line, revenue revenue XX% included of the exchange. The grew organic components our QX a increase our top year-over-year. growth X% reported benefit
growth a tailwind full the X% For increased revenue in XX%. a XX% XXXX, contribution foreign reported year This organic from and includes exchange.
geographies. Turning growth to by our
grew grew very grew just of including rest approximately all quarter, the grew Europe which North XX%, the over grew America world China, approximately regions strong and Pacific XX%; During XX%; approximately delivered growth. Asia XX%; XX%.
Europe X% XX%. Pacific grew XX%, America the world over full grew year, grew rest of the approximately over and XX%, just grew For North Asia
operating points margin operating operational QX year. XXX income our adjusted adjusted than QX higher XX.X%, and was to basis performance. last increased Turning XXX%;
volume to adjusted to basis the by System XX% the exceptional offset and year, For full strategic enabled income and of near adjusted leverage, partially full all our XXX our long-term investments was operating the we businesses In mix. and us also support quarter which was favorable points drive and This is growth. higher business year, operating had across our for margin increased Business XXXX. than XX.X%, PPI
quarter to the P&L. company the of XXX XX.X%, up the margin basis QX Total year. on in Moving the from of points gross adjusted came in at details prior
gross adjusted basis For margin the up year. XXX was XX.X%, versus year, full prior points
the due in to the the adjusted drivers and quarter our same leverage. due revenue, was points the both those Adjusted increase XX gross was fourth margin. basis full For of volume in XX% decrease of margin operating year, versus the strong to XXXX quarter the as for SG&A QX a
and For year, for revenue, the basis and expense high-impact representing of SG&A Total year, adjusted an XX% innovation. XXX respectively, $X.X full QX of $XXX for of reflecting growth was to was R&D increased in investments full compared XX%, improvement million XXXX. our XX.X% points the billion
our results for mainly an Looking debt. for approximately and the at million, the line QX in Net XXXX. interest FX. million, full of than million $XX our $XX expense million, in was expense than last $XXX XXXX, due due the higher quarter from lower year, below non-operating $X interest of income a other net of million expense $XX million higher level was increase to to changes the QX $XXX Adjusted primarily net quarter, year was expense
lower income and prior $XX expense income net was year. $XX adjusted of than year, other which a full million the the was For million,
last rate versus adjusted Our XXX QX was XX%, quarter in basis the up tax year. points
XXXX. million the and to or diluted substantial increase higher year-over-year rate shares For QX, in was The year, profit tax was year-over-year, dilution coming in tax our about impact due repurchases. pre-tax XXX XX.X% the XXX were basis marginal the driven points in X than rate lower the tax increase the adjusted by net share option at million Average of in full rate.
were For diluted the full shares year, the average XXX million.
billion, our for flow billion. $X.X cash expenditure from cash flow capital increased XX% cash increase year. to net balance continuing of delivering net highlight Cash was was $X.X $X.X while was growth Cash another flow the a We capital operations sheet. expenditures flow. the were billion the significantly in to free free and Turning execution accelerate and flow strategy great
of During dividends, with XXXX, through we returned approximately buybacks capital $XX.X total approximately cash we and $X.X QX and shareholders stock billion billion and in $XX.X billion debt. ended to of
basis adjusted debt the Our leverage ratio was total of on last And quarter QX our a XX.X%, generated X.X XXXX. adjusted X.X company gross and in concluding as year net returns times exceptional EBITDA performance, ROIC my XXX from at points the end to on we basis. was times comments debt up
lab-developed therapy in testing The genetic in segments. the From business biosciences had kits, includes our and businesses. color similar start businesses. some is with the provide revenue to clinical Solutions. revenue majority last recognized some from and response -- testing results. revenue our go that on this COVID-XX Life on and diagnostics in is Science tests controls performance the I'll COVID-XX includes that revenue preparation instruments, This revenue X of the from thoughts for standpoint, molecular segment the And segment vaccine quarter, on business the revenue into our Specialty sample response reagents kits. I'll and also recognized production Now in impacts framing segment There's the from supplies of bioproduction a Diagnostics biosciences the recognized sciences
across the Pharma market on revenue levels viral healthcare business. scale response channel. channel segment of in and Products Laboratory test from for recognized the media cold of Services and segment profitability manufactured PPE and for the revenue. used well the as as the plastics products equipment for lab that workflows differed therapy This transport our revenue in on We segments the -- different includes storage our microbiology also by and also a the the business. from in revenue business From and for based Services impact in includes margin our and vaccine the revenue services COVID-XX research testing market standpoint, of safety PPE and
businesses. of our make during with compensation that as response well segment, of the we The This each incentive in recognition in our investments. capability In investments strategic not margins. terms of investments commercial, COVID-XX colleagues across investments all does production included some in and as necessarily R&D size the and skew segment the to of revenue addition, does those continued align reported and so quarter,
management parts lot the from a segment a current margin company So future. and company, reflects even the of environment active position navigating of successfully standpoint moving very for the brighter an the
starting the Moving the and details, Life growth bioproduction revenue and Solutions. QX, quarter, organic In increased saw sciences and was exceptionally to genetic on In Science businesses. we XXX%. business segment with revenue reported XXX% strong growth our in biosciences
For reported and in was the mix, Science In XX.X%, up year, revenue we continued increased QX across volume very all operating Life XXX%, operating XX organic and segment. XX%. full business the percentage make businesses margin in this investments drove adjusted and and quarter, points was pull-through to year-over-year. income strong growth strategic positive we Solutions adjusted
We margins also had a from tailwind on FX.
was reported increased increase operating For percentage XX.X%, revenue was than an In increased End chemical organic materials strong in X%. of Instruments spectrometry XXX% year, revenue XXXX. businesses. for over adjusted the growth by chromatography the the operating in and XX adjusted analysis points muted, X% analysis this but segment, markets and full and and margin income more Analytical QX structural offset was and remain growth mass both
and drove activity We in of commercial continued customer these to levels businesses increased execution. strong see
the investments XX.X%, in year-over-year. productivity XXX offset Instruments the XX% points and Analytical full and operating margin X% decreased reported For was that the operating In adjusted basis the quarter, adjusted we segment I was revenue decreased organic declined down strategic earlier. by X%. than that more mentioned income year, drove strong very in revenue QX
segment. margins FX this We also from to in had a headwind
decline adjusted For margin XX% basis versus the decreased operating year. XXX operating full XX.X%, prior a income adjusted points and year, was of
to by the revenue QX, growth Turning In was reported revenue increased Diagnostics Specialty XXX%. segment. XXX%. Organic
below deliver still COVID-XX was but routine in and the levels, businesses. QX, The than QX diagnostics response testing our significant healthcare market businesses. level our in of channel us growth revenue pre-pandemic to enabling immunodiagnostics diagnostics for in microbiology, was clinical transplant and higher remains activity very diagnostics strong particularly quarter, Our
the was higher year drove up increased investments. For volume margin and In year. revenue in Adjusted the partially XXX% by QX, prior strategic XX.X%, operating revenue and than XX% full reported XX%. mix from year, was the was we growth offset organic and adjusted points operating strong leverage, negative prior income very basis XXX the was business which quarter
income channel, operating an year, versus and prior was For products revenue finally, increased growth reported was the a Services XX% and in full operating XX%. all of Organic year. pharma adjusted growth increased QX Laboratory safety the improvement XX%. segment, basis quarter, XX.X%, XX margin and adjusted points And we segment, the this research in our strong saw revenue in businesses In market laboratory and services. Products
is and mix revenue was full was year. XXX year, higher which than organic the margin than lower unfavorable points For XX% basis X.X%, prior business adjusted decreased the offset strategic productivity and and was strong than and QX, volume income was XX%. more XX% the XXXX reported revenue growth operating quarter, In adjusted In operating by in investments. segment leverage the
declined basis adjusted With of guidance year. We're XX% income the starting with the initial that, operating to XXX turn X% guidance. annual XX.X%, which was XXXX adjusted X% year, XXXX. EPS growth our prior lower operating full I'll the margin in over organic and result points than of year For growth adjusted will $XX.XX, and
pandemic outcomes serve demand demand potential positioned at year. operate for We around successful to aggressively testing. a for under to help exciting very performance. the exceptional how rather fluid, well of the And we're for company opportunities time, a multitude positioning growth to remain uniquely different year. full associated there and near the around the actually same with point out with another customers important for invest assumptions to long-term chosen our shareholders. to thought continue customer scale to be that year delivering We've along continued the of dynamics financial go outlook our it strong are than with frame view another a because this plays range performance The year, speed we'll incredibly at year, while initial of the give you was we especially scenario to any financial So very but
maximize in long-term just drive short So in stakeholders. will we XXXX, did and XXXX, our as for to all value we the opportunity
now the me assumptions provide initial behind our with you Let guidance.
In is organic X reported terms including represents of revenue, growth are There elements over our $XX.X XXXX, assumption. to key growth. X% X% which guidance the organic approximately growth billion,
base the First, business.
X% assuming growth XXXX. organic we're in Here,
COVID-XX the The second element is response.
XXXX; Here, therapy-related we're level with as plus This we year in roughly testing-related last for revenue we the revenue same in $X that's starting billion of assumption of an delivered which revenue is of XXXX, double reflects $X.X vaccine generated the the billion year. XXXX. approximately
you color on the me XXXX. revenue levels revenue. that revenue fairly similar XXXX. phasing testing-related QX of loaded response Let We're to linear is very the QX in COVID-XX front-end to assuming and be therapy assumed is vaccine give with some The
growth margin of in higher upside our acquisitions of to assumption. reported adjusted that the to and should later levels our Should guidance the year initial higher regards year. positioned We're have more progresses. the The longer the assumes of million really With guidance pandemic adjusted maintained, FX, sizable $X.X levels Our year. billion, X%. approximately in an testing testing customers, half a guidance second operating assumes well revenue X.X% than We'll this second be XX $XXX to demand may need than support contribute the or for the the in XX.X%, assuming particularly assuming demand moderate begin of as the on be points last tailwind actual in demand $X.XX initial or basis clarity then $XXX approximately lasting year-over-year then moderate to and of million We're QX we're potentially EPS XXXX. this half further year. will revenue to and
Our pull-through significant by productivity offset made drive to PPI will and investments benefits, will to that partially in System be those strong XXXX continue outlined Business volume strategic earlier. adding Marc
$X to that January. lower net $XX paydown non-operating in the the adjusted $X.X below assuming includes in million Moving XXXX, mainly be completed due expect due to billion million about we lower will This line, income FX. interest million. $XXX of other It expense is to be changes debt approximately we the debt. impact from million, lower We're by net in XXXX average net than XXXX $XX
capacity XXXX. The $X.X billion income primarily expect by rate of $X.X benefits increased assuming XX.X% approximately of in tax in investment over tax capital of growth, cash $XXX by flow pharma Free be an XXXX be is in driven billion. midpoint tax increase our $X earnings expenditure million by increase initiatives. expenditures primarily offset year billion in our expected planning from represents our We're XXXX, the investments. and by over adjusted bioproduction, is XXXX. to is The net approximately rate driven improvement Laboratory prior expected to biosciences the to capital XX% capability We businesses. and The expansions Products partially the driven services,
and $X.X be of includes completed XXX any guidance our This acquisition shareholders buybacks, approximately for of of share European we estimate in divestitures. million $X.X which share deployment. Our this million We $XXX does million consists or future vector it capital average guidance count of the capital shares, will full and assume Novasep's year returned through dividends. to recently $XXX billion acquisitions diluted not of business; year January; the completed that assumes billion viral approximately
not later quarterly include to there And does the wanted to to touch the factors finally, are as year it for of phasing QX. acquisition Mesa on consider. close several is I expected So which Biotech, in
first days half as X in year. the the X in the year. as XXXX is revenue that comparisons guidance for XXXX, a days significantly First, X the in significantly in extra to the I are COVID-XX and of first Then resulting note And in easier fewer included more selling the half less the response in of year. initial weighted reminder, full QX we the day mentioned have earlier, QX
to by XX% expected factors, in we're half, very total into organic of dynamics beginning the with QX an of in standpoint, similar growth in execution the growth year top-line And From QX reflecting be year. the taking of profile strong growth expecting to strong the the a of operational from the very and lot expecting then margin, of these quarter, So the of standpoint, half year. second account operating approximately the first a EPS year's throughout all XX% the impacting those XXXX. adjusted we're near-term and
track level, performance EPS growth and high of growth, with X% excellent record. starting revenue XX% organic the we're guidance year long-term of a financial at adjusted our continuation a So
on As over always, to best as back you progress turn our we'll Ken. we strive for the the go look to I'll that, to forward and the I deliver updating possible call year. through results, With
